However, as PD-1/PD-L1 inhibitors are used in a wider range of cancers, the need to evaluate the risk-benefit ratio of immunosuppressants used in cancer patients with preexisting autoimmune diseases will gradually increase. The gene discussed is CD274; the disease is cancer.